AstraZeneca has signed a $555 million deal with a San Francisco-based biotech business Algen Biotechnologies, The Financial Times reported on Monday. The agreement with Algen gives AstraZeneca ...

The agreement gives Chiesi exclusive rights for the development and commercialisation of ABO-101 to treat PH1.

A gene-editing tool that can turn genes on and off like a light switch has been developed. Turning a gene on means activating the production of ...

A gene-editing therapy led to durable changes in serum transthyretin levels among people with hereditary transthyretin ...

EXTON, PA, Aug. 14, 2025 (GLOBE NEWSWIRE) -- As the first wave of gene therapies for transfusion-dependent β-thalassemia (TDT) continues to roll out in the U.S., a new conversation is emerging within ...

Treatment introduces an expansion of the scope of gene therapies that might lead to similar treatments for neurodegenerative ...

Founded in 2020 by Chilean biochemist Bernardo Pollak, Meristem is using precise gene editing techniques to develop local ...

Cayman Chemical, a global provider of life science research tools, and Akadeum Life Sciences, a leader in buoyancy-based cell ...

In a development that could help protect one of the world's most beloved agricultural commodities, a research team at Penn ...

The inaugural Genetic Agency Technology Conference (GATC) on November 11th, 2025 will convene technical thought leaders, gene therapy developers, patients, their families, and patient advocates across ...

Researchers from the Department of Biomedical Engineering at UNIST and the Center for Genomic Integrity at the Institute for Basic Science (IBS) have announced an advance in cancer gene therapy. Their ...

Biotech company Factor Bioscience sued rival Cellectis and pharmaceutical giant AstraZeneca in Delaware federal court on ...